BIOGEN INC. Other Current Liabilities
BIOGEN INC. (BIIB) had Other Current Liabilities of $2.55 billion as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-04-29
- 2026-03-31: Other Liabilities, Current $2.55B.
- 2025-12-31: Other Liabilities, Current $2.80B.
- 2025-09-30: Other Liabilities, Current $2.77B.
- 2025-06-30: Other Liabilities, Current $2.66B.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-03-31 | $2.55B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $2.80B 10-Q · filed 2026-04-29 | |
| 2025-09-30 | $2.77B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $2.66B 10-Q · filed 2025-07-31 | |
| 2025-03-31 | $2.53B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $2.81B 10-K · filed 2026-02-06 | |
| 2024-09-30 | $2.76B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $2.47B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $2.35B 10-Q · filed 2024-04-24 | |
| 2023-12-31 | $2.62B 10-K · filed 2025-02-12 | |
| 2023-09-30 | $3.84B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $2.48B 10-Q · filed 2023-07-25 | |
| 2023-03-31 | $2.29B 10-Q · filed 2023-04-25 | |
| 2022-12-31 | $2.52B 10-K · filed 2024-02-14 | |
| 2022-09-30 | $3.31B 10-Q · filed 2022-10-25 | |
| 2022-06-30 | $3.30B 10-Q · filed 2022-07-20 | |
| 2022-03-31 | $2.23B 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $2.54B 10-K · filed 2023-02-15 | |
| 2021-09-30 | $2.55B 10-Q · filed 2021-10-20 | |
| 2021-06-30 | $2.74B 10-Q · filed 2021-07-22 | |
| 2021-03-31 | $2.59B 10-Q · filed 2021-04-22 | |
| 2020-12-31 | $3.15B 10-K · filed 2022-02-03 | |
| 2020-09-30 | $3.29B 10-Q · filed 2020-10-21 | |
| 2020-06-30 | $2.49B 10-Q · filed 2020-07-22 | |
| 2020-03-31 | $2.44B 10-Q · filed 2020-04-23 | |
| 2019-12-31 | $2.77B 10-K · filed 2021-02-03 | |
| 2019-09-30 | $2.43B 10-Q · filed 2019-10-22 | |
| 2019-06-30 | $2.32B 10-Q · filed 2019-07-24 | |
| 2019-03-31 | $2.44B 10-Q · filed 2019-04-24 | |
| 2018-12-31 | $2.86B 10-K · filed 2020-02-06 | |
| 2018-09-30 | $2.58B 10-Q · filed 2018-10-23 | |
| 2018-06-30 | $2.63B 10-Q · filed 2018-07-24 | |
| 2018-03-31 | $2.57B 10-Q · filed 2018-04-24 | |
| 2017-12-31 | $2.90B 10-K · filed 2019-02-06 | |
| 2017-09-30 | $2.46B 10-Q · filed 2017-10-24 | |
| 2017-06-30 | $2.44B 10-Q · filed 2017-07-25 | |
| 2017-03-31 | $2.04B 10-Q · filed 2017-04-25 | |
| 2016-12-31 | $2.90B 10-K · filed 2018-02-01 | |
| 2016-09-30 | $2.01B 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $2.07B 10-Q · filed 2016-07-21 | |
| 2016-03-31 | $2.00B 10-Q · filed 2016-04-21 | |
| 2015-12-31 | $2.10B 10-K · filed 2017-02-02 | |
| 2015-09-30 | $1.92B 10-Q · filed 2015-10-21 | |
| 2015-06-30 | $1.81B 10-Q · filed 2015-07-24 | |
| 2015-03-31 | $1.38B 10-Q · filed 2015-04-24 | |
| 2014-12-31 | $1.82B 10-K · filed 2016-02-03 | $1.82B 10-K · filed 2015-02-04 |
| 2014-09-30 | $1.54B 10-Q · filed 2014-10-22 | |
| 2014-06-30 | $1.50B 10-Q · filed 2014-07-23 | |
| 2014-03-31 | $1.22B 10-Q · filed 2014-04-23 | |
| 2013-12-31 | $1.36B 10-K · filed 2015-02-04 | |
| 2013-09-30 | $1.20B 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $1.06B 10-Q · filed 2013-07-25 | |
| 2013-03-31 | $885.09M 10-Q · filed 2013-04-25 | |
| 2012-12-31 | $979.95M 10-K · filed 2014-02-06 | |
| 2012-09-30 | $866.21M 10-Q · filed 2012-10-25 | |
| 2012-06-30 | $762.35M 10-Q · filed 2012-07-24 | |
| 2012-03-31 | $660.56M 10-Q · filed 2012-05-01 | |
| 2011-12-31 | $677.21M 10-K · filed 2013-02-05 | |
| 2011-09-30 | $674.74M 10-Q · filed 2011-10-28 | |
| 2011-06-30 | $641.27M 10-Q · filed 2011-07-26 | |
| 2011-03-31 | $591.45M 10-Q · filed 2011-04-21 | |
| 2010-12-31 | $665.92M 10-K · filed 2012-02-03 | |
| 2010-09-30 | $553.80M 10-Q · filed 2010-10-26 | |
| 2010-06-30 | $487.80M 10-Q · filed 2010-07-20 | |
| 2010-03-31 | $432.89M 10-Q · filed 2010-04-20 | |
| 2009-12-31 | $500.75M 10-K · filed 2011-02-04 | |
| 2009-09-30 | $537.41M 10-Q · filed 2009-10-21 | |
| 2009-06-30 | $496.69M 10-Q · filed 2009-07-17 | |
| 2008-12-31 | $534.89M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |